BRD4 inhibitor, (+)-JQ1, reduces triple-negative breast cancer growth and mammosphere formation. A Effect of JQ1 on the proliferation of MDA-MB-231 cells. The cells were cultured with the indicated concentration range of JQ1 for 24 h. Cell viability was measured using the MTS assay. B Inhibitory effect of mammosphere formation by JQ1. Treatment with 0.5 µM JQI reduced mammosphere formation to 20%. C Breast CSC marker, CD44+/CD24− expression in MDA-MB-231 cells. The cells were treated with 1 µM JQ1 for 1 day. CD44+/CD24− expression was evaluated using a flow cytometer. D CSC marker, ALDH expression in MDA-MB-231 cells. The cells were treated with 1 µM JQ1 for 1 day. ALDH expression was measured using the ALDEFLUOR assay kit and a flow cytometer, as described in the “Materials and methods” section. E CSC marker gene expressions in MDA-MB-231 cells treated with JQ1. The cells were treated with 0.5 µM JQ1 for 18 h. The mRNA levels of CD44, c-Myc, OCT4, and SOX2 were measured by reverse-transcription quantitative polymerase chain reaction. F Inhibitory effect of JQ-1 on mammosphere growth. JQ1-treated mammospheres were divided into single cells, and equal numbers of cells were cultured. The number of cells was analyzed daily for 3 days by counting. G Difference in BRD4 protein expression in breast cancer cells and mammospheres. BRD4 protein expression was analyzed in cancer cells and mammospheres derived from MDA-MB-231 and MCF-7 cells by Western blot, as described in the “Materials and methods” section. H Effect of BRD4 on mammosphere formation. After BRD4 knockdown using siRNA, mammosphere formation was reduced, as shown in the photos and graphs. The knockdown of BRD4 was verified by Western blot, and images of the mammosphere (right) were taken at ×10 magnification. I CSC marker, CD44+/CD24− expression on BRD4-knockdown cells. The cells were treated with siBRD4 for 2 days. CD44+/CD24 expression was evaluated using a flow cytometer. J CSC marker, ALDH, expression on BRD4-knockdown cells. The cells were treated with siBRD4 for 2 days. ALDH expression was measured using the ALDEFLUOR assay kit and a flow cytometer. Experiment values are represented as the mean ± SD of triplicates. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, * p < 0.05 BRD4 degrader ARV-825 inhibited mammosphere formation. A Molecular structure of BRD4 degrader ARV-825. B Proliferation assay using ARV-825 on MDA-MB-231 cells. The cells were cultured with increasing concentration range of ARV-825 for 24 h. C Effect of ARV-825 on BRD4 degradation. The cells were cultured using the indicated concentrations of ARV-825 for 24 h. D Effect of BRD4 degrader ARV-825 on mammosphere formation. ARV-825-treated mammosphere formation was reduced, as shown in the photos and graphs. Experiment values are represented as the mean ± SD of triplicates. E CSC marker, CD44+/CD24− expression on ARV-825-treated cells. The cells were treated with ARV825 for 24 h. CD44+/CD24 expression was evaluated using a flow cytometer. F CSC marker, ALDH expression on ARV-825-treated cells. The cells were treated with ARV825 for 24 h. ALDH expression was measured using the ALDEFLUOR assay kit and a flow cytometer. G CSC-related gene expression on ARV-825-treated cells. The cells were treated with 0.5 µM ARV-825 for 18 h. The mRNA levels of CD44, c-Myc, OCT4, and SOX2 were measured by reverse-transcription quantitative polymerase chain reaction. H Inhibitory effect of ARV-825 on mammosphere growth. ARV825-treated mammospheres were divided into single cells, and equal numbers of cells were cultured. The number of cells was analyzed daily for 3 days by counting. Experiment values are represented as the mean ± SD of triplicates. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, * p < 0.05 BRD4 degrader ARV-825 inhibited PD-L1 expressions, and PD-L1 regulated mammosphere formation. A PD-L1 protein expression in breast cancer cells and mammospheres. PD-L1 protein expressions were analyzed in cancer cells and mammospheres derived from MDA-MB-231 and MCF-7 cells by Western blot, as described in the “Materials and methods” section. B Transcriptional regulation of PD-L1 genes by BRD4 inhibitor JQ1 and ARV-825-treated MDA-MB-231 cells and mammospheres. The cells were treated with 0.5 µM JQ1 and 0.5 µM ARV-825 for 18 h. The mRNA level of PD-L1 was measured using reverse-transcription quantitative polymerase chain reaction. C PD-L1 protein levels in mammospheres after treatment of the BRD4 inhibitor and ARV-825. The mammospheres were treated with 1 µM JQ1 and 0.5 µM ARV-825 for 24 h. D, E Fractional analysis of PD-L1 protein expression in mammospheres. Cell lysate was fractionated using an isolation kit, as described in the “Materials and Methods” section. The mammospheres of MDA-MB-231 cells were treated with 1 µM JQ1 or 0.5 µM ARV-825 for 24 h. The fractions were analyzed by Western blot with PD-L1 antibody, and subcellular location markers were detected with antibodies (α-tubulin, ATPase, Lamin-B, and vimentin). F PD-L1 reporter luciferase assay using MDA-MB-231 cells and mammospheres. PD-L1 reporter plasmid was transfected into cancer and mammosphere, and cells were then treated with 1 µM JQ1 and 0.5 µM ARV-825 for 24 h. The cells were lysed, and luciferase was assayed as described in the “Materials and methods” section. G Chromatin immunoprecipitation (ChIP) assay on the promoter of PD-L1 gene using anti-BRD4. The binding site of BRD4 on the CD274 (PD-L1) gene is shown in Fig. 3G. Mammospheres were treated with 1 µM JQ1 or 0.5 µM ARV825. ChIP analysis using an antibody against BRD4 and the negative control IgG. H Effect of PD-L1 on mammosphere formation. Cultured MDA-MB-231 cells were treated with siPD-L1 for 2 days. The mammospheres derived from siPD-L1 cells were cultured for 7 days. PD-L1 knockdown was verified by Western blot. Experiment values are represented as the mean ± SD of triplicates. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, * p < 0.05 PD-L1-regulated RelB gene-regulated mammosphere formation. A Regulation of PD-L1 expression in mammosphere by verteporfin, a PD-L1 degrader. The cells were treated with 2 µM verteporfin for 18 h. The mRNA levels of PD-L1 were measured by reverse-transcription quantitative polymerase chain reaction (RT-qPCR). The protein expression of PD-L1 was detected by Western blot. The cells were treated with 2 and 4 µM verteporfin for 24 h. B Transcriptional regulation of RelB by PD-L1 inhibition. After treatment of 2 µM verteporfin for 18 h, the mRNA levels of RelB were measured by RT-qPCR. The cells were treated with 2 and 4 µM verteporfin for 24 h, and the protein expression of RelB was detected by Western blot. C Transcriptional and translational regulations of RelB through BRD4 inhibition. The mRNA levels of RelB were measured by RT-qPCR. The cells were treated with 1 µM JQ1 or 0.5 µM ARV-825 for 18 h. The protein expression of RelB was detected by Western blot. The cells were treated with 1 µM JQ1 or 0.5 µM ARV-825 for 24 h. D Regulation of mammosphere formation by RelB. Cultured MDA-MB-231 cells were transfected with si-RelB for 2 days. The mammospheres derived from si-RelB-transfected cells were incubated for 7 days. RelB knockdown was verified by Western blot. The mammosphere images (right) were taken at ×10 magnification. E Inhibitory effect of RelB inhibitor calcitriol on mammosphere formation. Proliferation of calcitriol-treated cells was measured using the MTS assay. The cells were treated with an increasing concentration range of calcitriol for 24 h. Mammospheres derived from MDA-MB-231 cells were treated with the indicated concentrations of calcitriol for 7 days. The RelB-inhibitory effect of calcitriol was verified by Western blot. Mammosphere images (right) were taken at ×10 magnification. Experiment values are represented as the mean ± SD of triplicates. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, * p < 0.05 RelB/p65 complex regulated mammosphere formation. A CoIP assay. CoIP assay was performed in mammospheres derived from MDA-MB-231 cells. The cell lysate was incubated with the RelB antibody or corresponding IgG. The immunoprecipitants were blotted with p65 or p50. The RelB/p65 complex was verified through the IP assay of p65. B Mammosphere formation regulation of p65. Cultured MDA-MB-231 cells were transfected with si-p65 for 2 days. Mammospheres derived from si-p65-transfected cells were incubated for 7 days. p65 knockdown was verified by Western blot, and mammosphere images (right) were taken at ×10 magnification. C Inhibitory effect of p65 inhibitor caffeic acid phenethyl ester (CAPE) in triple-negative breast cancer cells and mammospheres. The proliferation of CAPE-treated cells was measured using the MTS assay. The cells were treated with increasing concentration range of CAPE for 24 h. Mammospheres derived from MDA-MB-231 cells were given indicated concentrations of CAPE for 7 days. The RelB-inhibitory effect of CAPE was verified by Western blot of nuclear fraction. 20 µM CAPE was used to perform Western blot. Experiment values are represented as the mean ± SD of triplicates. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, * p < 0.05 RelB/p65 complex regulated IL-6 transcriptional expression. A Effect of calcitriol and caffeic acid phenethyl ester on interleukin (IL)-6 and IL-8 of mammospheres. Mammospheres were treated with 40 µM calcitriol or 20 µM caffeic acid phenethyl ester for 18 h. mRNA levels of IL-6 and IL-8 were analyzed by reverse-transcription quantitative polymerase chain reaction (RT-qPCR). B Effect of BRD4 inhibitor on IL-6 gene expression on mammosphere. Mammospheres were treated with 1 µM JQ1 or 0.5 µM ARV-825 for 18 h. mRNA levels of IL-6 were analyzed by RT-qPCR. C Effect of PD-L1 inhibitor on IL-6 gene expression on mammospheres. Mammospheres were treated with 4 µM verteporfin for 18 h. mRNA levels of IL-6 were analyzed by RT-qPCR. D ChIP assay on the promoter of IL-6. The binding site of NF-kB on IL-6 promoter is shown in Fig. 6D. Mammospheres were treated with 40 µM calcitriol. ChIP analysis used an antibody against p65 or RelB. The negative control used was IgG. E Cytokine profiling in mammospheres. Cytokine profiling was performed at the drug-treated mammosphere culture medium, and the drug concentrations were as follows: 1 µM JQ1, 0.5 µM ARV-825, 4 µM verteporfin, 40 µM calcitriol, or 20 µM caffeic acid phenethyl ester. The amounts of IL-6 and IL-8 were quantified using a flow cytometer. F Rescue experiment using PD-L1 overexpression plasmid to confirm the existence of the BRD4/PD-L1/RelB/IL-6 axis. Protein expression regulation by ARV-825 in breast cancer. The PD-L1 expression plasmid vector, pEGFP-N1/PD-L1 was transfected into MDA-MB-231 cells and the transfected cancer cells were treated with 0.5 µM ARV-825 for 24 h. The protein expressions of BRD4, PD-L1, and RelB were detected by Western blot. Cytokine profiling was performed at ARV-825-treated cancer cell culture medium. The amount of IL-6 was quantified using a flow cytometer. Experiment values are represented as the mean ± SD of triplicates. Experiment values are represented as the mean ± SD of triplicates. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, * p < 0.05 BRD4 inhibitory natural compound 3',4',7,8-tetrahydroxyflavone (THF) regulated mammosphere formation derived from MDA-MB-231 and ARV-825 inhibits mammosphere formation derived from HCC1937 through the inhibition of BRD4/PD-L1/RelB. A Structure of THF. B Inhibitory effect of THF on the proliferation of MDA-MB-231 cells. The cells were cultured with the indicated concentration range of THF for 24 h. Cell viability was measured using the MTS assay. C Inhibitory effect of THF on mammosphere. The mammospheres derived from MDA-MB-231 cells were treated with the indicated concentrations of THF for 7 days. Mammosphere images (right) were taken at ×10 magnification. D Protein expression regulation by THF in mammospheres. The protein expressions of c-Myc, PD-L1, and RelB were detected by Western blot. The cells were treated with 100 µM THF for 24 h. E Protein expression regulation of THF in nuclear and cytosolic fractions of mammospheres. The protein expressions of c-Myc, PD-L1, and RelB were detected by Western blot. The cells were treated with 100 µM THF for 24 h. F Transcriptional regulation of THF on mammosphere. The cells were treated with 100 µM THF for 18 h. mRNA levels of PD-L1, RelB, and IL-6 were analyzed using reverse-transcription quantitative polymerase chain reaction. G Cytokine profiling in mammospheres. Cytokine profiling was performed at THF (100 µM)-treated mammosphere culture medium. The amount of IL-6 was quantified using a flow cytometer. H Proliferation assay using ARV-825 on breast cancer cell line, HCC1937 cells. The cells were cultured with an increasing concentration range of ARV-825 for 24 h. I Effect of BRD4 degrader ARV-825 on mammosphere formation. ARV-825-treated cells reduced mammosphere formation, as shown in the photos and graphs. Experiment values are represented as the mean ± SD of triplicates. J CSCs marker, ALDH expression on ARV-825-treated cells. The cells were treated with ARV-825 for 24 h. ALDH expression was measured using the ALDEFLUOR assay kit and a flow cytometer. K Protein expression regulation of ARV-825 in mammosphere derived from HCC1937. The protein expressions of c-Myc, PD-L1, and RelB were detected by Western blot. The cells were treated with 0.1 µM ARV-825 for 24 h. L IL-6 level of mammospheres under ARV-825 treatment. The level of IL-6 was examined in the ARV-825 (0.1 µM)-treated mammosphere culture medium. The amount of IL-6 was quantified using a flow cytometer. Experiment values are represented as the mean ± SD of triplicates. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, * p < 0.05 BRD4 inhibitory natural compound 3',4',7,8-tetrahydroxyflavone (THF) regulated the formation of tumorspheres derived from MC38 cells. A The inhibitory effect on the cell proliferation of THF in mouse colon cells (MC38 cells). The cells were cultured with the indicated increasing concentration range of THF for 24 h. Cell viability was measured using the MTS assay. B The inhibitory effect of tumorsphere formation by THF. Tumorspheres derived from MC38 cells were treated with 200 µM THF for 7 days. Tumorsphere images (right) were taken at ×10 magnification. C CSC marker, ALDH expression of MC38 cells. The cells were treated with 200 µM THF for 1 day. ALDH expression was measured using the ALDEFLUOR assay kit and a flow cytometer, as described in the “Materials and methods” section. D THF induced apoptosis in tumorspheres derived from MC38 cells. The tumorspheres were treated with 200 µM THF for 1 days. Apoptosis was analyzed using Annexin V/PI staining, as described in the “Material and methods” section. E Protein expression regulation of THF in tumorspheres. The protein expressions of c-Myc, PD-L1, and RelB were detected by Western blot. The cells were treated with 200 µM THF for 24 h. F Protein expression regulation of THF in the nuclear and cytosolic fractions of tumorspheres. The protein expressions of c-Myc, PD-L1, and RelB were detected by Western blot. The cells were treated with 200 µM THF for 24 h. G IL-6 level of tumorspheres under THF treatment. The level of IL-6 was examined in the THF (100 µM)-treated tumorspheres culture medium. The amount of IL-6 was quantified using a flow cytometer. Experiment values are represented as the mean ± SD of triplicates. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, *p < 0.05 Effect of 3',4',7,8-tetrahydroxyflavone (THF) on tumor growth and immune response in mouse models. A In vivo experimental schedule. B Effect of THF of the mouse tumor. Mice were inoculated with MC38 cells and treated with THF. The body weight and tumor volumes of the mice were monitored for 25 days. After being sacrificed, tumor weight was determined. n = 5 in each group. C Protein expression regulation of THF in the tumor. The protein expressions of c-Myc, PD-L1, and RelB in tumors were detected by Western blot. D, E CSC marker, ALDH, expression of tumor or tumor-draining lymph nodes (TDLNs). Tumors or TDLNs were isolated into single cells, as described in the “Materials and methods” section. ALDH expression was measured using the ALDEFLUOR assay kit and a flow cytometer. F, G Helper T-cells or cytotoxic T-cells contained in the tumors and TDLNs. Tumors or TDLNs were isolated into single cells and analyzed using CD3+/CD4+ or CD3+/CD8+ staining, as described in the “Materials and methods” section. Compared with the control as determined by student’s t-test or one-way ANOVA with Dunnett’s multiple comparisons tests, *p < 0.05 Proposed model for cancer stem cell formation and immune response by BRD4/PD-L1/RelB/IL-6. The BRD4 protein transcriptionally regulated the PD-L1 gene, and PD-L1 protein transcriptionally regulated the RelB gene. The RelB/p65 complex regulates IL-6 transcripts. The BRD4/PD-L1/RelB/IL-6 axis regulated breast CSC formation